Compound profile
Humanin
EmergingAlso known as: MDP humanin · HN
A 24-amino-acid peptide encoded within mitochondrial DNA itself, part of a growing family of "mitochondrial-derived peptides" (alongside MOTS-c) studied in aging and cellular-stress biology.
Overview
Humanin is a short peptide with an unusual origin: it is encoded not in the nuclear DNA that makes up most of the human genome, but within mitochondrial DNA itself, inside a region that was previously thought to only code for ribosomal RNA. That makes it one of the founding examples of what researchers now call mitochondrial-derived peptides, a small family of signaling molecules, including the related peptide MOTS-c, that mitochondria produce beyond their traditional job of generating cellular energy.
The peptide was independently described in 2001 by two research groups working separately. Ikuo Nishimoto's laboratory in Japan identified it while screening for factors that protected neurons from dying in tissue taken from Alzheimer's disease brains, and a parallel group led by Yuichi Hashimoto reported similar findings around the same time. That Alzheimer's-adjacent discovery context set the tone for a lot of the research that followed, which has focused heavily on humanin's protective effects on cells under metabolic or toxic stress.
Since its discovery, humanin has mostly stayed in the realm of cell biology and animal research. Pinchas Cohen's laboratory at USC later expanded the mitochondrial-derived peptide family and has driven much of the field's growth, but no human interventional trial of humanin or a humanin analogue currently exists. What exists instead is observational human data: circulating humanin levels can be measured and tracked, and those measurements are where most of the human-relevant evidence currently sits.
Mechanism (plain language)
Binds proapoptotic proteins and a receptor complex involving gp130/WSX1/CNTF receptor subunits, giving it cytoprotective and neuroprotective effects in cell and animal models under toxic or metabolic stress.
How it works
Humanin's best-characterized effect in cell and animal models is protecting cells from dying under stress. It appears to bind proapoptotic proteins, meaning proteins that would otherwise push a stressed cell toward programmed cell death, and interferes with that process. Separately, it engages a cell-surface receptor complex built from gp130, WSX1, and CNTF receptor subunits, the same general receptor family used by certain cytokines, which triggers protective, survival-oriented signaling inside the cell.
Together, these actions give humanin cytoprotective and neuroprotective effects in laboratory models exposed to toxic or metabolically stressful conditions, consistent with the neuron-survival context in which it was first discovered. In humans, circulating humanin levels naturally decline with age, but researchers have found that levels are notably higher in the children of centenarians, people with an above-average likelihood of healthy long life themselves, and levels are reduced in some age-related conditions including Alzheimer's disease. Those associations are suggestive of a role in healthy aging, but they are correlational: humanin levels track with these outcomes, which is different from proving that boosting humanin levels would cause the outcomes to improve.
What research suggests
Animal work shows humanin overexpression extends lifespan in C. elegans and improves metabolic and cognitive healthspan markers in aged mice. In humans, circulating humanin levels decline with age but are notably higher in children of centenarians, and levels are reduced in conditions like Alzheimer's disease. This is correlational human data, not interventional trials.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Lifespan and healthspan extension in animal models
Research reported that humanin overexpression extended lifespan in C. elegans (roundworms) and improved metabolic and cognitive healthspan markers in aged mice, though mouse lifespan itself was not extended.
Association with exceptional human longevity
Circulating humanin levels are reported to be higher in children of centenarians compared with the general population, an association researchers use to support its role in healthy aging.
Exercise-responsive signaling
A human study found that acute high-intensity interval exercise raised circulating and muscle humanin levels in men, linking it to exercise physiology.
Neuroprotective activity in cell and animal models
Laboratory research describes humanin protecting neurons from toxic and metabolic stressors, consistent with the context in which it was first discovered.
Uncertainties & risks
No human interventional trials of humanin or its analogues exist yet. Its short in-vivo half-life (roughly 20 minutes) limits translation, and mouse lifespan itself was not extended even though healthspan markers improved. Marketing claims exceed the current human evidence base.
The gap between what has been shown for humanin and what gets claimed about it online is significant. There are currently no human interventional trials of humanin or any humanin analogue, meaning no study has given people humanin and measured what happened to a health outcome. Everything at the human level so far is observational, correlating naturally occurring humanin levels with age, health status, or exercise, which can generate hypotheses but cannot establish that raising humanin levels artificially would produce the same benefits. Practical translation is also a real hurdle. Humanin's natural half-life in the body is short, on the order of about 20 minutes, which limits how useful the native peptide would be even if human trials existed, and is part of why researchers have developed longer-acting analogues like HNG for laboratory study. It is also worth noting that even in the foundational mouse study, overall lifespan was not extended despite improvements in specific healthspan markers, a distinction that is easy to lose in secondhand summaries. Marketing claims around humanin as a longevity compound currently run well ahead of the evidence base.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.